- Hemostemix (HEM) has trademarked “Your Fountain of Youth”
- This registration will be valid for 10 years
- The registration has been sent by the International Bureau to the offices of 107 designated countries who are each a signatory to the Madrid Agreement
- The results of the 106 subjects suffering from ischemic cardiomyopathy ” had improved cardiac function (Left Ventricle Ejection Fraction), improved exercise capacity, and improved quality of life
- Hemostemix Inc. (HEM) is down 6.90 per cent, trading at C$0.14 at 9:30 am EST
Hemostemix’s (HEM) intellectual property holding company Kwalata Trading Limited has trademarked “Your Fountain of Youth”.
Hemostemix has been granted International Trademark Registration No. 1624069 valid for a period of 10 years.
In receipt of notices from both the World Intellectual Property Organization and the European Union Intellectual Property Office, the registration has been sent by the International Bureau to the offices of 107 designated countries who are each a signatory to the Madrid Agreement.
“In a trademark, Your Fountain of Youth translates the science of ACP and the business of Hemostemix into an easy-to-understand, centuries long-sought-after concept,” said CEO, Thomas Smeenk.
As witnessed clinically and published in the Phase I and Phase II studies of 262 subjects, ACP is safe and it works,” added Thomas Smeenk.
The results of the 106 subjects suffering from ischemic cardiomyopathy “[experienced] improved cardiac function (Left Ventricle Ejection Fraction), improved exercise capacity, and improved quality of life…”
The results of 41 subjects treated by direct injection of ACP into the heart to treat ischemic and dilated cardiomyopathy.
The 83 per cent of subjects treated compassionately for critical limb ischemia who “… had clinically significant improvement of adequate circulation at the distal limb for…complete healing.”
The interim results from its Phase II CLI trial (abstract presentation), which noted healing of ulcers and resolution of ischemic rest pain occurred in 83 per cent of patients, with outcomes maintained for up to four and a half years.
Hemostemix is a publicly-traded autologous stem cell therapy company, founded in 2003.
A winner of the World Economic Forum Technology Pioneer Award, the company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
Hemostemix Inc. (HEM) is down 6.90 per cent, trading at C$0.14 at 9:30 am EST.
